Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.45 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 2/20 | 0.37 |
| ▸ | BID | P55957 | 3/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.36 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.36 |
| ▸ | BAK1 | Q16611 | 2/20 | 0.36 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | EP300 | Q09472 | 1/20 | 0.36 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.36 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.36 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.36 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.36 |
| ▸ | THRA | P10827 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL983948 | 0.98 | LTA4H (0.44) | LTA4HLIPGPPARABIDMCL1 | |
| SCHEMBL983439 | 0.95 | LTA4H (0.45) | LTA4HLIPG | |
| SCHEMBL981223 | 0.89 | LTA4H (0.40) | LTA4HPPARAPPARG | |
| SCHEMBL979987 | 0.82 | LTA4H (0.40) | LTA4H | |
| SCHEMBL4728624 | 0.79 | HTR1A (0.38) | LTA4H | |
| SCHEMBL3812990 | 0.79 | SLC6A2 (0.44) | LTA4H | |
| SCHEMBL983303 | 0.78 | LTA4H (0.42) | LTA4HPPARAPPARG | |
| SCHEMBL980128 | 0.78 | LTA4H (0.42) | LTA4HLIPGPPARAPPARG | |
| SCHEMBL10659939 | 0.78 | LIPG (0.44) | LTA4HLIPGALOX5PTGS2PPARA | |
| SCHEMBL984698 | 0.78 | LTA4H (0.42) | LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2275406-B1 | PROCESS FOR PRODUCING ISOCYANATE | ASAHI CHEMICAL IND (JP) | 2018-11-28 | — | — | EP | disclosed |
| US-9233918-B2 | Isocyanate production process | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2016-01-12 | — | — | US | disclosed |
| US-20110092731-A1 | ISOCYANATE PRODUCTION PROCESS | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
| EP-2275406-A1 | PROCESS FOR PRODUCING ISOCYANATE | Asahi Kasei Chemicals Corporation (JP) | 2011-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092731-A1 | ISOCYANATE PRODUCTION PROCESS | CPS1, PHGDH, APEH | LTA4H 1039/4885LIPG 28/4885ALOX5 1229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.